Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A live Pharma & Life Sciences Clinical and Evidence Strategy file in an RWE group proposing a post-marketing study instead of a new RCT now turns on biosimilar analytical similarity report after an AdCom briefing document that overstates subgroup findings. Labeling negotiator should state what that extract proves for whether to drop a secondary endpoint that will dominate the AdCom.

DECISION Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. The population in biosimilar analytical similarity report is the one an AdCom briefing document that overstates subgroup findings named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in biosimilar analytical similarity report is adjacent only to an AdCom briefing document that overstates subgroup findings; Pause the pathway is the honest Pharma & Life Sciences call. 3. An RWE group proposing a post-marketing study instead of a new RCT already contained an AdCom briefing document that overstates subgroup findings before biosimilar analytical similarity report arrived; no new Clinical and Evidence Strategy path. 4. Provenance on biosimilar analytical similarity report after an AdCom briefing document that overstates subgroup findings is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether biosimilar analytical similarity report supports the labeled claim labeling negotiator would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after an AdCom briefing document that overstates subgroup findings). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after an AdCom briefing document that overstates subgroup findings, then the two facts that force it, then the Monday action for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.